AI Article Synopsis
- The study investigates how Roux-en-Y gastric bypass (RYGB) affects ghrelin, a hormone linked to appetite, in obese women with type 2 diabetes (T2D).
- It finds that after RYGB, the expression of the ghrelin gene (GHRL) increases in the excluded stomach but not in other areas of the gastrointestinal tract.
- However, no significant changes in ghrelin levels in the bloodstream were observed, and there was no relationship found between ghrelin levels and diabetes remission after surgery.
Article Abstract
Background: Mechanisms of type 2 diabetes remission (T2Dr) after Roux-en-Y gastric bypass (RYGB) in obese patients appear to involve gastrointestinal hormones.
Objective: The objective of this study is to explore changes in ghrelin plasma levels and ghrelin gastrointestinal gene expression (GHRL) after RYGB, and their relationships to T2Dr.
Setting: In 20 obese women with T2D, before and 3 months after RYGB, we assessed GHRL expression by microarray and quantitative RT-PCR in gastrointestinal biopsy samples and plasma levels of ghrelin.
Results: After RYGB, GHRL expression increased in the excluded stomach (p < 0.05) with no change in other gastrointestinal sites. There were no significant changes in ghrelin plasma levels and no correlations with T2Dr.
Conclusions: After RYGB, over-expression of GHRL gene occurs only in the excluded stomach with no correlation to T2Dr.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11695-017-3098-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!